secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001213900-26-036937
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics reports Q4 net loss of $3.0M, cash $4.0M; CAD-1005 FDA EOP2 meeting completed
--------------------------------------------------------------------------------

- Q4 2025 net loss $3.0M vs $4.2M YoY; R&D expenses $0.7M vs $1.5M; G&A $2.4M vs $2.7M.
- Cash and equivalents $4.0M at Dec 31, 2025; evaluating financing and strategic alternatives to support clinical development.
- Completed End-of-Phase 2 FDA meeting on March 26, 2026 for CAD-1005; Phase 3 pivotal trial protocol incorporation underway.
- Phase 2 HIT study showed >25% absolute reduction in thrombotic events with CAD-1005 vs placebo on standard anticoagulation.
- CAD-1005 has Orphan Drug and Fast Track designations from FDA; orphan status from EMA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026036937/0001213900-26-036937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026036937/ea0284258-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-036937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer